Latest European Association for the Study of Diabetes Stories
WORCESTER, Mass., Sept.
RIDGEFIELD, Conn., Sept.
PARIS, Sept. 20 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.
DANBURY, Conn., July 1 /PRNewswire-FirstCall/ -- Biodel Inc.
JACKSONVILLE, Fla., June 29 /PRNewswire-USNewswire/ -- On June 26, 2009 several articles published online in Diabetologia by the European Association for the Study of Diabetes investigated the possible relationship between use of insulin glargine (Lantus, sanofi-aventis) and the development of certain malignancies.
The European Association for the Study of Diabetes (EASD) has announced a discovered link between French drug maker Sanofi-Aventisâ€™ Lantus diabetes drug and cancer.
WORCESTER, Mass., Oct.
A panel of experts convened by the American Diabetes Association and the European Association for the Study of Diabetes has issued updated treatment recommendations for type 2 diabetes, in a consensus statement being published online today in the journals Diabetes Care and Diabetologia.
PARIS, September 10 /PRNewswire-FirstCall/ -- - Abstracts 186 and 1003 Sanofi-aventis announced today that results from two studies, GINGER and LACE, presented at the 44th annual meeting of the European Association for the Study of Diabetes (EASD) demonstrated that a basal-bolus insulin regimen with LANTUS(R) (insulin glargine (rDNA origin) injection) once daily (basal insulin) and rapid-acting APIDRA(R) (insulin glulisine [rDNA origin] injection) at mealtime (bolus insulin) produced...
At the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Rome, Biodel Inc.
- totally perplexed and mixed up.